Nuvalent's promising trial results and FDA designations for its drug candidates increase its attractiveness as an acquisition target. The mention of potential suitors like Pfizer, AstraZeneca, and Novartis highlights the interest from major players. The company's strong financial position and cash runway until 2028 further support a positive outlook. However, potential risks such as regulatory setbacks and competition are noted, but the overall sentiment is positive.